Söndag 22 December | 05:01:26 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-05-16 N/A Årsstämma
2025-02-28 08:00 Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-09-04 - Extra Bolagsstämma 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-08 - X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 - Kvartalsrapport 2022-Q1
2022-05-06 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-22 - Extra Bolagsstämma 2021
2021-06-09 - X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-12 - Extra Bolagsstämma 2020
2020-05-13 - X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-22 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 - Bokslutskommuniké 2018
2018-12-13 - Extra Bolagsstämma 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2023-11-21 08:30:00

Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB's products and services. The project will use ISAB's XposeALI in vitro exposure module.

ISAB's XposeALI in vitro cell exposure module is connected to the company's multi-modular aerosol generating platform PreciseInhale. The set-up delivers a precise and even dispersion of test aerosol particles directly onto the cell surface, hence the exposure is called "Air-Liquid Interface", simulating what occurs on the lung lining when the drug is inhaled.

Reducing test substance costs

The cost of test substances and animal testing is a substantial and growing expense in the development of inhaled therapies. The XposeALI in vitro method significantly reduces the amount of test materials required, as PreciseInhale allows customizable doses of aerosol using minimal amounts of test substance. A full PK study using PreciseInhale can require as little as 100 milligrams of test substance compared to 100g using conventional methods.

Minimizing animal testing

In vitro testing is growing in importance also in the frame of regulatory guidelines, possibly reducing the future need for animal testing. This not only cuts costs but also aligns with 3R guidelines, a guiding framework on the ethical use of animals recognized by much of the industry and its funding bodies.

Leading the way in in vitro testing

ISAB is increasingly gaining a reputation as a leading innovator and provider of in vitro research services, offering permeability and dissolution studies for inhaled drug development through instruments like XposeALI and its in vitro dissolution testing module DissolvIt.

CEO Manoush Masarrat: "Once again we're witnessing the growing demand for advanced in vitro testing systems like XposeALI, as the powerful benefits are increasingly understood and recognized. We extend a warm welcome to our returning client".

Discover ISAB's in vitro testing modules[ ]